Benefits
Stress + cortisol attenuation + cognition (Allen 2016 PIVOTAL)
Allen AP, Hutch W, Borre YE, Kennedy PJ, Temko A, Boylan G, Murphy E, Cryan JF, Dinan TG, Clarke G 2016 (Transl Psychiatry, doi:10.1038/tp.2016.191, PMID 27845782, PMC5314114) — translational psychobiotic study in N=22 healthy volunteers, within-participants design. Cognitive assessments + resting EEG + socially evaluated cold pressor test at baseline, post-placebo, post-psychobiotic. RESULTS: ATTENUATED INCREASES in CORTISOL OUTPUT and SUBJECTIVE ANXIETY in response to social stressor. REDUCED daily reported stress. Subtle improvements in HIPPOCAMPUS-DEPENDENT VISUOSPATIAL MEMORY performance. ENHANCED FRONTAL MIDLINE EEG MOBILITY. Foundational pivotal study supporting psychobiotic claims.
Brain neural oscillations modulation (PMC6615936 MEG 4-week RCT)
PMC6615936 (Am J Gastroenterol) — randomized double-blind placebo-controlled trial. 40 healthy volunteers received B. longum 1714™ or placebo for 4 weeks at 1×10^9 CFU/day. NEURAL responses to social stress (Cyberball game standardized social stress paradigm) measured by MAGNETOENCEPHALOGRAPHY. RESULTS: B. longum 1714™ ALTERED RESTING-STATE NEURAL OSCILLATIONS — INCREASE in THETA BAND POWER in FRONTAL and CINGULATE CORTEX (P<0.05). Foundational neuroimaging evidence for direct brain modulation.
Low mood + depressive symptoms 8-week RCT (NCT04925440)
NCT04925440 — randomized double-blind placebo-controlled QUADRUPLE-MASKED parallel trial sponsored by PrecisionBiotics Group Ltd. RECENTLY COMPLETED. Population: adults with LOW MOOD. Intervention: 5×10^9 CFU B. longum 1714® strain capsules vs placebo for 8 WEEKS. Primary outcome: BECK'S DEPRESSION INVENTORY-II SCORE. Important emerging mood/depression evidence beyond healthy volunteer studies.
Sleep quality improvement (Allen 2016 secondary findings)
Allen 2016 + subsequent observations: improved subjective sleep quality and duration with B. longum 1714 1×10^9 CFU/day. Note: study population was male only, age 18-30 — limited generalizability. Mechanism: gut-brain axis modulation supporting circadian regulation + stress reduction.
Hippocampus-dependent visuospatial memory (Allen 2016)
Allen 2016 demonstrated SUBTLE IMPROVEMENTS in HIPPOCAMPUS-DEPENDENT VISUOSPATIAL MEMORY performance with psychobiotic consumption. Important: hippocampus is critical for memory consolidation + spatial cognition + stress response regulation. Mechanism: gut-brain axis modulation of hippocampal function — distinct from typical nootropic mechanisms.
Frontal midline EEG mobility enhancement (Allen 2016)
Allen 2016 — ENHANCED FRONTAL MIDLINE EEG MOBILITY following psychobiotic consumption. Frontal midline activity associated with attention, working memory, executive function. Mechanism: gut-brain axis modulation of cortical activity. Foundational electrophysiological evidence for direct brain effects.
Theta band power increase (PMC6615936 mechanism)
PMC6615936 demonstrated INCREASE in THETA BAND POWER in FRONTAL and CINGULATE CORTEX with B. longum 1714. Theta oscillations associated with: meditation states, memory encoding, emotional regulation, stress resilience. Mechanism: direct gut-brain axis modulation of resting-state cortical activity. Distinguishing neurophysiological signature.
Mechanism of action
Gut-brain axis modulation (psychobiotic mechanism)
B. longum 1714 acts as PSYCHOBIOTIC — strain-specific gut bacteria affecting brain function via gut-brain axis. Mechanisms: vagal afferent signaling, short-chain fatty acid production (SCFAs), neurotransmitter precursor production, immune modulation. Foundation mechanism for stress + cognitive effects.
HPA axis cortisol response attenuation
Allen 2016 mechanism: ATTENUATED CORTISOL OUTPUT in response to acute social stressor. Mechanism: gut-brain axis modulation of HPA axis reactivity. Important for chronic stress states + stress-related conditions.
Hippocampal function modulation
Allen 2016 — improvements in hippocampus-dependent visuospatial memory. Mechanism: gut-brain axis modulation of hippocampal neuronal activity + plasticity. Distinguishing from typical nootropic mechanisms.
Cortical theta + frontal midline EEG modulation
PMC6615936 + Allen 2016 — direct cortical activity modulation evidenced by EEG/MEG. Theta oscillation increase + frontal midline mobility enhancement. Mechanism: gut-brain axis affecting cortical neural oscillations.
Stress response regulation
Reduces stress-related behaviors in preclinical studies + reduces daily reported stress + attenuates acute stress response in humans. Mechanism: combined HPA axis + cortical + autonomic nervous system regulation via gut-brain signaling.
Strain specificity (1714 distinct from other B. longum)
B. longum 1714 effects are STRAIN-SPECIFIC — not generalizable to other B. longum strains. Different B. longum strains (NCC3001, BL999, etc.) produce different effects. Foundation principle: probiotic effects are strain-specific, not species-specific. Important for product selection.
Clinical trials
Translational psychobiotic study (Allen AP, Hutch W, Borre YE, Kennedy PJ, Temko A, Boylan G, Murphy E, Cryan JF, Dinan TG, Clarke G 2016, Transl Psychiatry, doi:10.1038/tp.2016.191, PMID 27845782, PMC5314114). University College Cork APC Microbiome Institute.
N=22 healthy volunteers. Within-participants design: cognitive assessments + resting EEG + socially evaluated cold pressor test at baseline, post-placebo, post-psychobiotic. B. longum 1714 1×10^9 CFU/day for 4 weeks.
ATTENUATED CORTISOL OUTPUT + SUBJECTIVE ANXIETY in response to socially evaluated cold pressor test. REDUCED daily reported stress. Subtle improvements in HIPPOCAMPUS-DEPENDENT VISUOSPATIAL MEMORY. ENHANCED FRONTAL MIDLINE EEG MOBILITY. Foundational pivotal study supporting psychobiotic claims. Within-participants design + small N (22) limits some generalizability but demonstrates clear translational psychobiotic effects.
Randomized double-blind placebo-controlled trial (PMC6615936, Am J Gastroenterol, Wang H, Braun C, Murphy EF, Enck P).
40 healthy volunteers. B. longum 1714™ 1×10^9 CFU/day or placebo for 4 weeks. Brain activity measured by MAGNETOENCEPHALOGRAPHY during Cyberball social stress paradigm. SF-36 health survey.
B. longum 1714™ ALTERED RESTING-STATE NEURAL OSCILLATIONS — INCREASE in THETA BAND POWER in FRONTAL and CINGULATE CORTEX (P<0.05). Foundational neuroimaging evidence for direct brain modulation. Industry-related funding (Alimentary Health) noted.
Randomized double-blind placebo-controlled QUADRUPLE-MASKED PARALLEL TRIAL (NCT04925440, sponsored by PrecisionBiotics Group Ltd, COMPLETED).
Adults with LOW MOOD/depressive symptoms. B. longum 1714® 5×10^9 CFU/day capsules vs placebo for 8 WEEKS. Primary outcome: BECK'S DEPRESSION INVENTORY-II SCORE.
STATUS: COMPLETED — important emerging mood/depression evidence beyond healthy volunteer studies. Higher dose (5×10^9 CFU/day) than Allen 2016 (1×10^9). 8-week duration provides longer evidence base. Industry-sponsored (PrecisionBiotics) — important context.
About this ingredient
BIFIDOBACTERIUM LONGUM 1714 is a SPECIFIC BIFIDOBACTERIUM LONGUM SUBSP. LONGUM STRAIN commercialized by ALIMENTARY HEALTH GROUP / PrecisionBiotics as ZENFLORE™ branded food supplement (also trademarked as 1714-SERENITAS™). PROVEN PSYCHOBIOTIC — first-generation strain demonstrating strain-specific cognitive + stress effects via gut-brain axis. Distinguished from other B. longum strains (NCC3001, BL999, etc.) — probiotic effects are STRAIN-SPECIFIC not species-specific. PIVOTAL CLINICAL EVIDENCE: ALLEN 2016 PMID 27845782 PMC5314114 (Transl Psychiatry, doi:10.1038/tp.2016.191) — translational psychobiotic study at University College Cork APC Microbiome Institute (N=22 healthy volunteers, within-participants design, 1×10^9 CFU/day for 4 weeks) demonstrating ATTENUATED CORTISOL OUTPUT + SUBJECTIVE ANXIETY in response to socially evaluated cold pressor test, REDUCED daily reported stress, SUBTLE IMPROVEMENTS in HIPPOCAMPUS-DEPENDENT VISUOSPATIAL MEMORY, ENHANCED FRONTAL MIDLINE EEG MOBILITY. PMC6615936 (Am J Gastroenterol, Wang H, Braun C, Murphy EF, Enck P) — randomized double-blind placebo-controlled trial in 40 healthy volunteers using MAGNETOENCEPHALOGRAPHY during Cyberball social stress paradigm — B. longum 1714™ ALTERED RESTING-STATE NEURAL OSCILLATIONS with INCREASE in THETA BAND POWER in FRONTAL and CINGULATE CORTEX (P<0.05). NCT04925440 (RECENTLY COMPLETED) — 8-week quadruple-masked RCT in adults with LOW MOOD using 5×10^9 CFU/day with Beck's Depression Inventory-II primary outcome — important emerging mood/depression evidence beyond healthy volunteer studies. PRECLINICAL EVIDENCE: McKernan 2010 visceral antinociceptive effects in rats; multiple stress-related behavior studies in animals.
MECHANISMS: GUT-BRAIN AXIS modulation (psychobiotic mechanism — vagal afferent signaling, SCFAs, neurotransmitter precursors, immune modulation); HPA AXIS cortisol response attenuation; HIPPOCAMPAL FUNCTION modulation; CORTICAL THETA + FRONTAL MIDLINE EEG modulation; STRAIN SPECIFICITY (1714 distinct from other B. longum strains). EVIDENCE: 3/5 reflects: (1) ALLEN 2016 PIVOTAL PSYCHOBIOTIC TRANSLATIONAL TRIAL with multi-domain stress/cognitive/EEG benefits in healthy volunteers, (2) PMC6615936 MEG NEUROIMAGING RCT — direct brain activity modulation evidence (theta band increase frontal/cingulate cortex), (3) NCT04925440 RECENTLY COMPLETED 8-week LOW MOOD RCT (industry-sponsored), (4) WELL-CHARACTERIZED gut-brain axis psychobiotic mechanism, (5) STRAIN-SPECIFIC clinical evidence base distinct from other B. longum strains, (6) MULTIPLE mechanistic studies (McKernan 2010 rat antinociceptive, etc.), (7) industry-sponsorship (Alimentary Health Group / PrecisionBiotics) — important context but methodology rigorous (APC Microbiome Institute Cork — internationally recognized), (8) SMALL SAMPLE SIZES across studies (N=22 in Allen 2016, N=40 in PMC6615936) limit generalizability, (9) higher-evidence than typical probiotic supplement due to dedicated psychobiotic research program. SAFETY: Excellent — food-grade probiotic with multiple human trials supportive. Best positioned as: (a) STRESS REDUCTION + cortisol response attenuation adjunct (Allen 2016 cold pressor evidence), (b) MILD MOOD support adjunct (NCT04925440 emerging evidence — pending publication), (c) WORKING MEMORY + visuospatial memory subtle support (Allen 2016 hippocampus-dependent), (d) SOCIAL STRESS resilience adjunct (Cyberball MEG evidence), (e) DAILY long-term use acceptable based on safety profile, (f) ZENFLORE™ branded product preferable for clinical evidence-matched formulation, (g) PREGNANCY: limited specific data; food-grade origin supports general safety, (h) IMMUNOCOMPROMISED: caution (applies to all probiotics), (i) ANTIBIOTIC USERS: take 2-3 hours apart, (j) higher-evidence than typical probiotic 'mood support' supplement due to dedicated multi-modal research program (clinical + EEG + MEG + cognitive). Honest framing: Bifidobacterium longum 1714 (Zenflore™) is one of the BEST-CHARACTERIZED PSYCHOBIOTICS with multi-modal clinical evidence (clinical + EEG + MEG + cognitive testing). Allen 2016 is a foundational psychobiotic translation study from preclinical to human clinical effects. PMC6615936 MEG neuroimaging evidence is genuinely distinctive — direct brain activity modulation evidence rare among probiotics. Strain-specificity emphasis is scientifically sound — different B. longum strains produce different effects. NCT04925440 emerging low mood RCT will provide important depression-specific evidence. Industry-sponsorship (Alimentary Health Group) warrants caveat but APC Microbiome Institute Cork (independent academic site) collaboration supports methodology. Sample sizes remain small (N=22 in Allen 2016, N=40 in PMC6615936) — important caveat for definitive conclusions. Reasonable mild stress + cognitive support adjunct based on evidence — particularly compelling for those wanting evidence-based psychobiotic with neuroimaging-supported brain effects.